Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
Abstract Background The anti-fibrotic medications nintedanib and pirfenidone were approved in the United States for use in patients with idiopathic pulmonary fibrosis several years ago. While there is a growing body of evidence surrounding their clinical effectiveness, these medications are quite ex...
Збережено в:
| Автори: | , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
BMC
2022-01-01
|
| Серія: | BMC Pulmonary Medicine |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1186/s12890-021-01811-0 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|